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INTRODUCTION
Ticagrelor, a rapid-onset, direct-acting P2Y12 receptor antago-
nist, demonstrated superior short- and long-term clinical out-
comes over clopidogrel in large clinical trials.1,2 In addition to 
antagonizing P2Y12 receptor, ticagrelor has been reported to 
block adenosine receptor in patients with acute myocardial 
infarction (AMI) and increase endothelial progenitor cell 
numbers, which may contribute to endothelial regeneration.3,4 
However, it is still unknown if ticagrelor accelerates neointi-
mal healing at an early period after percutaneous coronary 
intervention (PCI) in patients with AMI. Therefore, we sought 
to compare the effect of ticagrelor and clopidogrel on strut cov-
erage at 3 months after drug-eluting stent (DES) implantation 
in patients with AMI, using optical coherence tomography 
(OCT).
MATERIALS AND METHODS
Study population
This study was designed as a prospective, open-label, ran-
domised controlled trial (NCT02037412). Patients (aged 20–80 
years) with AMI who were undergoing early invasive strategy 
were eligible for this study. Exclusion criteria were as follows: 
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Purpose: This study aimed to compare the effects of ticagrelor and clopidogrel on early neointimal healing assessed with optical 
coherence tomography (OCT) after drug-eluting stent (DES) implantation in patients with acute myocardial infarction (AMI).
Materials and Methods: AMI patients were randomly assigned to either the ticagrelor or clopidogrel arm. After DES implanta-
tion, OCT was performed to assess the percentages of uncovered struts immediately after procedure and 3 months later.
Results: Due to early termination, 83 patients out of 106 initially enrolled patients (24% of planned participants) underwent 
3-month OCT. Differences in vascular healing patterns between the two groups, including percentage of uncovered struts on 
3-month OCT (9.6% vs. 11.7% in ticagrelor vs. clopidogrel, respectively; p=0.867), neointimal thickness, percentage of malap-
posed struts, and healing scores did not reach statistical significance. The predictors of uncovered strut on 3-month OCT includ-
ed greater reference vessel diameter [odds ratio (OR)=1.96, p<0.001] and more malapposed struts (OR=1.12, p=0.003).
Conclusion: The current study did not explore favorable effect of ticagrelor on 3-month vascular healing after DES implantation. 
Our findings should only be considered for generating hypothesis, due to insufficient power.
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1) any contraindication to ticagrelor or clopidogrel, 2) cardio-
genic shock, 3) PCI without stent implantation, 4) anemia or 
thrombocytopenia, 5) oral anticoagulation therapy, 6) preg-
nancy or potential for childbearing in women, and 7) life ex-
pectancy of <12 months. Study protocol was separately ap-
proved by the Institutional Review Board of each participating 
institute (IRB No. 4-2013-0764), and all patients signed a writ-
ten informed consent form.
Randomization and procedures
Eligible patients were randomly assigned in a 1:1 ratio to re-
ceive either ticagrelor or clopidogrel, using an interactive web-
based response system with a permuted block randomisation 
method. The patients received aspirin (300 mg as a loading 
dose or 100 mg if previously administered) and a loading dose 
of the study drug (180 mg of ticagrelor or 300 to 600 mg of clopi-
dogrel) before PCI. All patients with ST-elevation AMI under-
went primary PCI. For revascularisation of culprit lesions, only 
thin-strut biodegradable polymer sirolimus-eluting stent (Or-
siro; Biotronik AG, Bülach, Switzerland) was allowed. Opera-
tor was able to use OCT imaging before or after stent implan-
tation, if clinically needed. Operator evaluated OCT findings 
during the procedure, and decided to use further adjuvant bal-
looning for stent optimization. Final OCT (post-procedural) 
was performed at the treated culprit before completing the pro-
cedure. Patients took aspirin and study drug as allocated with-
out cross-over during the study period, and underwent 3-month 
follow-up OCT.
Endpoints
Primary endpoint was the percentage of uncovered struts on 
3-month OCT. Secondary endpoints were neointimal thickness 
and increased malapposition on 3-month OCT.
OCT imaging and analysis
OCT images were acquired by a frequency-domain OCT sys-
tem (C7-XRTM OCT imaging system; LightLab Imaging Inc., St. 
Jude Medical, St. Paul, MN, USA). OCT images were recorded 
at 100 frames/s, while catheter was pulled back at 20 mm/s 
within stationary imaging sheath. Acquired imaging data were 
analyzed with certified offline software (QIvus; Medis Medical 
Imaging System, Leiden, the Netherlands) at a core laboratory 
(Cardiovascular Research Center, Seoul, Korea) by indepen-
dent analysts who were blinded to patient and procedural in-
formation. Contiguous cross-sectional images were quantita-
tively measured in 1-mm intervals along the entire stented 
segment. Stent and luminal cross-sectional areas (CSAs) were 
measured. Neointimal CSA was calculated as stent CSA minus 
lumen CSA. An uncovered strut was defined as having a neo-
intimal thickness of 0 μm.5,6 Neointimal thickness was mea-
sured as the distance between endoluminal surface of neo-
intima and strut. A malapposed strut was defined as a strut that 
had detached from the vessel wall by ≥90 μm (110 μm for stents 
≥3.5 mm in diameter).7,8 Malapposed stent was further classi-
fied into persistent, resolved, and late-acquired by matching 
the OCT images obtained at post-procedure and 3-month fol-
low-up.6 To comprehensively evaluate vascular responses, we 
adopted the definition of healing score as the weighted index 
based on OCT findings related to stent characteristics; a high 
score reflected higher incidence of uncovered or malapposed 
struts.9
Quantitative coronary angiography analysis
Quantitative coronary angiography analysis was performed 
before and after PCI and at 3 months, using an offline comput-
erized quantitative coronary angiographic system (CASS sys-
tem; Pie Medical Instruments, Maastricht, the Netherlands) 
in an independent core laboratory (Cardiovascular Research 
Center, Seoul, Korea). Minimal lumen diameter and reference 
diameters of coronary lesions were measured in view with the 
narrowest lumen and the least amount of foreshortening, in 
comparison to the diameter of guidance catheter from diastolic 
frames in a single, matched view.
Statistical analysis
We assumed that the mean percentage of uncovered struts on 
3-month OCT was 6.2% in the control group with AMI (stan-
dard deviation, 6.9%) based on our previous OCT study10, and 
hypothesized that the use of ticagrelor might achieve further 
improvement to 2% uncovered struts when compared with 
clopidogrel. We considered a total of 444 subjects to be suffi-
cient to demonstrate the superior strut coverage of ticagrelor 
considering a 15% dropout rate (80% power at 5% significance 
level).
Categorical data were expressed as number (%), and ana-
lyzed with χ2 statistics or Fisher’s exact test. Continuous vari-
ables were expressed as mean±standard deviation or median 
(interquartile range), and were compared using Student’s t-test 
or Mann-Whitney test. Considering the clustered nature of 
data, a generalized linear mixed model was applied for strut-
level and cross-section-level analysis while comparing the two 
study drugs with a patient indicator (patient and cross-section 
for strut level; patient for cross-section level) as a random ef-
fect and the study drug as a fixed effect. To determine the pre-
dictors for uncovered struts, strut-level analysis was applied us-
ing each clinical, quantitative coronary angiography-derived, 
and OCT-derived variable as a fixed effect. For modeling with 
multiple fixed effects, all variables having fixed effect with a p-
value of <0.10, and ticagrelor use were entered into the model. 
In backward elimination manner, we sequentially deleted one 
non-significant interaction with the largest p-value at a time 
to obtain a parsimonious final model. A generalized linear 
model was also used to determine the predictors of increased 
malapposition between post-procedure and 3-month follow-
up. To assess the reproducibility of measuring uncovered and 
malapposed struts, 50 cross-sections (504 struts) were ran-
626
Ticagrelor for Early Strut-Coverage in AMI
https://doi.org/10.3349/ymj.2018.59.5.624
domly chosen at follow-up OCT. Inter- and intra-observer 
variabilities in OCT measurements of distance and area were 
previously reported.11 All statistical analyses were performed 
with R Statistical Software (version 3.3.2; R Foundation for 
Statistical Computing, Vienna, Austria). P-value <0.05 was 
considered statistically significant.
RESULTS
After a 2-year recruitment period, investigators and data safe-
ty monitoring board agreed to terminate the study before 
achieving target recruitment due to the following reasons: 1) 
slower patient enrollment than expected, 2) recently updated 
guidelines recommending the preferential use of ticagrelor in 
AMI patients, 3) evidence to ensure consistently favorable ef-
fects in Asian patients with ticagrelor12, and 4) overwhelming 
use of ticagrelor for AMI patients in Korea.13 Between March 
2014 and March 2016, a total of 106 patients who met the 
study criteria underwent PCI. A detailed explanation of study 
flow is provided in Fig. 1. All lesions were treated with Orsiro 
stent as planned. Both groups were well-matched for clinical, 
angiographic, procedural characteristics (Table 1), and post-
procedural OCT findings (Table 2).
Three-month follow-up OCT
Difference in the percentages of uncovered struts between ti-
cagrelor (9.6%) and clopidogrel groups (11.7%) did not reach 
statistical significance (p=0.867). There were no significant 
differences between groups in neointimal thickness, percent-
ages of malapposed struts, or occurrence of late-acquired 
malapposition. Other levels of analyses showed no significant 
differences between groups (Table 3, Fig. 2). Furthermore, 
healing scores did not differ between the two groups (Fig. 3). 
Inter- and intra-observer variabilities were 0.970 and 0.990 for 
evaluation of uncovered struts, and 0.990 and 0.990 for malap-
posed struts, respectively.
Factors affecting 3-month strut coverage
Including the use of ticagrelor and angiographic covariates as 
fixed effects into model 1, only reference vessel diameter was 
identified as a significant predictor of strut coverage. Further 
modeling with OCT-derived variables, model 2 determined 
the final independent predictors including reference vessel 
diameter [odds ratio (OR) 1.96, 95% confidence interval (CI) 
1.43–2.68, p<0.001] and percentage of malapposed struts (OR 
1.12, 95% CI 1.04−1.22, p=0.003) (Table 4). However, there 
were no significant clinical variables, including the use of ti-
cagrelor, affecting strut coverage on 3-month OCT. Lesions 
were divided into four groups based on the median values of 
two significant predictors (reference vessel diameter, 3.02 
mm; percentage of malapposed struts, 1.86%), and strut cov-
erage was compared. Lesions with greater vessel diameter and 
more malapposition showed the highest rate of uncovered 
struts compared with other lesions (Fig. 4).
On serial OCT, percentage of malapposed struts was in-
creased in 30 lesions (36%). Significant factors for increasing 
malapposition were total occlusion on initial angiogram (ad-
Between Mar 2014 and Mar 2016, 128 AMI  
patients were initially assessed
PCI with stenting
Excluded: PCI not performed (n=4) Excluded: PCI not performed (n=5)
Total 115 AMI patients were randomised
Ticagrelor loading dose (n=58) Clopidogrel loading dose (n=57)
Excluded: Unstable condition (n=6)
No planned angiography (n=3)
Refusal to participate (n=4)
Maintain ticagrelor 90 mg bid
Ticagrelor group (n= 54, PCI performed)
Postprocedural OCT (n=52)
Excluded: not performed due to patients condition (n=2)
Follow-up OCT at 3 months (n=43)
Excluded: patients’ refusal (n=8), follow-up loss (n=1)
Maintain clopidogrel 75 mg qd
Clopidogrel group (n= 52, PCI performed)
Postprocedural OCT (n=49)
Excluded: not performed due to patients condition (n=2), 
poor image quality (n=1)
Follow-up OCT at 3 months (n=40)
Excluded: patients’ refusal (n=9)
Fig. 1. Study design and flow of patient inclusion. AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; OCT, optical coherence 
tomography.
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Table 1. Baseline Clinical and Treatment Characteristics
Variables Ticagrelor (n=43) Clopidogrel (n=40) p value
Age (yr) 60±24 62±12 0.448
Male 35 (81) 34 (85) 0.885
DM   7 (16)   6 (15) >0.999
Hypertension 21 (49) 18 (45) 0.897
Dyslipidaemia 26 (60) 18 (45) 0.234
Renal insufficiency   0 (0)   1 (3) 0.971
Current smoker 21 (49) 18 (45) 0.897
Prior MI   0 (0)   0 (0) >0.999
Admission via emergency room 39 (91) 37 (93) >0.999
Clinical diagnosis 0.583
Non-ST elevation MI 13 (30)   9 (22)
ST elevation MI 30 (70) 31 (78)
Left ventricular ejection fraction (%) 48±10 48±10 0.889
Coronary intervention within 24 hours after hospital visit 41 (95) 36 (90) 0.606
Culprit lesion, left anterior descending artery 26 (60) 21 (53) 0.739
Thrombolysis in myocardial infarction flow 0 or 1 
  on initial angiogram
24 (56) 18 (45) 0.444
Intracoronary thrombus 24 (56) 25 (63) 0.692
Quantitative coronary angiography
Pre-procedure 
Reference vessel diameter (mm) 3.1±0.5 3.2±0.6 0.407
Lesion length (mm) 17 (14−22) 19 (15−26) 0.209
Post-procedure 
Minimal lumen diameter (mm) 2.8±0.4 2.8±0.4 0.570
Acute gain (mm) 2.4±0.6 2.3±0.6 0.174
Stent diameter (mm) 3.0 (3.0−3.5) 3.3 (3.0−3.5) 0.387
Stent length (mm) 18 (18−24) 22 (18−30) 0.100
Stent inflation pressure (atm)   8 (8−12) 8 (8−10) 0.125
Aspiration thrombectomy 21 (49) 17 (43) 0.720
Adjunctive post-dilatation 15 (35) 13 (33) >0.999
Post-dilatation balloon diameter, (mm) 3.5 (3.0−3.5) 3.5 (3.0−3.5) 0.483
Maximal post-dilatation pressure (atm) 16 (10−16) 12 (10−16) 0.604
Use of intra-aortic balloon pump   0 (0)   2 (5) 0.442
Use of glycoprotein IIb/IIIa inhibitors   2 (5)   4 (10) 0.606
No reflow after stenting   0 (0)   1 (3) 0.971
Medication at discharge
Aspirin 43 (100) 40 (100) >0.999
Statins 43 (100) 40 (100) >0.999
Beta-blockers 33 (77) 34 (85) 0.500
Angiotensin-converting enzyme or angiotensin II 
  receptor blocker
34 (79) 28 (70) 0.486
Medication at 3-month follow-up*
Ticagrelor 43 (100) - -
Clopidogrel - 40 (100) -
Statins 43 (100) 40 (100) >0.999
Beta-blockers 31 (72) 32 (80) 0.559
Angiotensin-converting enzyme or angiotensin II receptor 
blocker
28 (65) 26 (65) >0.999
DM, diabetes mellitus; MI, myocardial infarction. 
Values are n (%), mean±standard deviation, or median (interquartile range).
*Values were obtained among patients undergoing 3-month optical coherence tomography.
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justed OR 3.21, 95% CI 1.21−8.98, p=0.021) and thrombus vi-
sualized on post-procedural OCT (adjusted OR 2.98, 95% CI 
1.07−8.68, p=0.040). Percentage of uncovered struts in the le-
sions with increased malapposition was significantly higher 
than that in the lesions with reduced malapposition or non-
malapposition (median, 17.6% vs. 7.6%; p<0.001).
Table 2. Post-Procedural Optical Coherence Tomography Characteristics
Variables Ticagrelor (n=43) Clopidogrel (n=40) p value
Total number of cross sections   882   911
Total number of analysable struts 9519 9604
Mean stent CSA (mm2) 7.2±1.7 7.9±2.4 0.128
Minimal stent CSA (mm2)   5.7 (5.0−6.8)   5.9 (5.0−7.7) 0.266
Percentage of malapposed struts (%)   3.0 (0.5−5.5)   2.3 (0.0−6.0) 0.832
Percentage of cross sections with any malapposed strut (%) 13.3 (5.4−22.9) 10.8 (0.0−25.8) 0.790
Malapposed stent (%)    33 (77)    29 (73) 0.848
Total malapposed volume (mm3)   3.9 (2.2−5.8)   3.3 (1.5−7.7) 0.985
Maximal malapposed CSA (mm2)   0.6 (0.4−1.1)   0.6 (0.3−1.5) 0.760
Maximal length of segments with malapposed struts (mm)   2.0 (1.0−3.0)   1.0 (0.0−4.0) 0.956
Plaque protrusion (%)    34 (79)    35 (88) 0.464
Intraluminal thrombi (%)      9 (21)    16 (40) 0.098
Edge dissection (%)      9 (21)      8 (20) >0.999
CSA, cross-sectional area.
Values are n (%), mean±standard deviation, or median (interquartile range).
Table 3. OCT Characteristics at 3 Months
Variables Ticagrelor Clopidogrel p value
Number of patients followed 43 40 -
Duration between baseline and follow–up OCT (days) 99±10 100±10 0.675
Strut-level analysis
Total number of analysable struts 9730 9895
Percentage of uncovered struts (%) 9.6 (5.8–20.4) 11.7 (3.7–20.1) 0.867
Neointimal thickness (μm)  51 (34–61)    48 (35–61) 0.885
Percentage of malapposed struts (%) 1.2 (0.0–3.7)   1.0 (0.0–2.5) 0.771
Cross-section-level analysis
Total number of cross sections 851 872
Mean lumen CSA (mm2) 7.3 (5.8–8.1)   7.3 (5.8–9.0) 0.097
Mean stent CSA (mm2) 7.5 (6.2–8.5)   7.7 (6.2–9.4) 0.081
Mean neointimal CSA (mm2) 0.3 (0.1–0.5)   0.3 (0.1–0.5) 0.325
Percentage of neointimal CSA (%) 3.7 (1.4–6.8)   3.9 (1.7–7.2) 0.655
Cross-sections with any uncovered strut (%)  56 (38–76)    57 (33–77) 0.907
Cross-sections with a ratio of uncovered to total struts >0.3 (%) 7.4 (0.0–32.5) 11.8 (0.0–34.3) 0.957
Cross-sections with any malapposed strut (%)  12 (0–28)    10 (0–23) 0.779
Stent-level analysis
Uncovered stent  42 (98)    40 (100) >0.999
Malapposed stent 0.472
Persistent  28 (65)    22 (55)
Resolved    5 (12)      7 (18)
Late-acquired    2 (5)      5 (13)
Minimal stent CSA (mm2) 6.2 (5.0–7.1)   6.4 (5.3–8.1) 0.272
Intrastent thrombi    0 (0)      0 (0) >0.999
Total malapposed volume (mm3) 2.4 (0.9–5.4)   1.9 (0.5–4.8) 0.645
Maximal malapposed CSA (mm2) 0.6 (0.4–1.2)   0.5 (0.3–1.2) 0.402
Maximal length of segment with malapposed struts (mm)    2 (0–4)      1 (0–3) 0.419
CSA, cross-sectional area; OCT, optical coherence tomography.
Values are n (%), mean±standard deviation, or median (interquartile range).
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DISCUSSION
The current study was the first human trial comparing the ef-
fect of ticagrelor and clopidogrel on early strut coverage after 
DES implantation in patients with AMI. However, the present 
OCT study was terminated early (24% of planned participants 
enrolled), and underpowered to assess the superior effect of 
ticagrelor over clopidogrel on 3-month vascular healing in 
AMI patients; there were no significant differences in percent-
age of uncovered struts, neointimal thickness, or healing scores 
on 3-month OCT between groups.
Previous studies demonstrated beneficial effects of ticagre-
lor on vascular healing. Ticagrelor is known to increase the 
number of endothelial progenitor cells in patients with acute 
coronary syndrome.4 It may offer some benefit for the regen-
eration of endothelial cells, which modulate the reconstruc-
tion of neointima.14 In vivo study demonstrated a correlation 
between accelerated re-endothelialization and inhibition of 
neointimal formation after balloon injury.15 Ticagrelor was re-
ported to inhibit deleterious neointimal growth after vascular 
injury in the mouse16 and rabbit carotid models.17 However, 
the effect of ticagrelor on early phase of vascular healing still 
requires further investigation.
OCT-defined strut coverage has been widely used as a sur-
rogate indicator for vascular healing after stent implanta-
tion.18,19 However, the process of vascular healing includes in-
flammation, cellular proliferation, and extracellular matrix 
deposition,20 which may not be differentiated with current 
OCT methods. Thin-layered fibrin or thrombus may be con-
fused with neointimal coverage. Considering these limitations 
of OCT, the clinical implications of early strut coverage should 
be further investigated, and more advanced systems are need-
ed. An upcoming OCT technology with greater resolution and 
various cell-tagging methods might help in understanding 
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Fig. 2. Comparisons of strut coverage between ticagrelor and clopidogrel: (A) uncovered strut, (B) neointimal thickness, (C) cross-sections with un-
covered strut, and (D) cross-sections with uncovered strut >3. Thick lines within boxes represent median value; upper and lower margins of boxes 
represent 25th and 75th percentiles, respectively; and upper and lower bars represent 90th and 10th percentiles, respectively.
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further processes of vascular healing after DES implantation.21
In our analyses, there were no significant clinical factors, in-
cluding the use of ticagrelor, to predict strut coverage on 
3-month OCT. Significant factors were vessel size and the de-
gree of stent apposition on post-procedural OCT, suggesting 
that stent optimisation by improving apposition considering 
vessel size is more important for improving early strut coverage. 
As for lower strut coverage in larger vessels, various factors 
could be involved. First, under the setting of PCI for AMI, small-
er diameter stents tend to be chosen and vigorous high-pres-
sure post-dilation is hesitated, especially in large-vessel culprit 
lesions, owing to the risk of serious no-reflow after stenting. 
Also, it may be more difficult to determine the optimal stent 
size in large vessels due to the more dynamic variability of ves-
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Fig. 3. Cumulative distribution of optical coherence tomography healing 
scores. IQR, interquartile range.
Table 4. Predictors for Uncovered Strut at 3 Months
Variables
Simple model Model 1 Model 2
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Clinical variables
Age, per 10 years 1.10 (0.86–1.41) 0.453
DM 1.43 (0.65–3.15) 0.380
ST-elevation MI 0.75 (0.39–1.45) 0.393
Use of ticagrelor 1.05 (0.59–1.88) 0.867 1.13 (0.66–1.93)   0.653 1.14 (0.67–1.94)   0.639
Angiographic variables
Reference vessel diameter, per 1 mm 2.14 (1.57–2.92) <0.001 2.15 (1.58–2.93) <0.001 1.96 (1.43–2.68) <0.001
Stent diameter, per 1 mm 1.88 (0.93–3.81) 0.077 –* –* –* –*
Acute gain, per 1 mm 1.59 (0.99–2.54) 0.056 –* –* –* –*
Thrombus on initial angiography 1.84 (0.94–3.61) 0.077 –* –* –* –*
OCT-derived variables
Intraluminal thrombus 1.71 (0.94–3.23) 0.079 –* –*
Mean stent CSA, per 1 mm2 1.13 (1.03–1.24) 0.009 –* –*
Percentage of malapposed strut, per 10% 1.17 (1.08–1.26) <0.001 1.12 (1.04–1.22)   0.003
CI, confidence interval; OR, odds ratio; DM, diabetes mellitus; MI, myocardial infarction; OCT, optical coherence tomography; CSA, cross-sectional area.
*Backward elimination was used to conduct a parsimonious final model.
sel diameter in the case of coronary artery occlusion or severe 
stenosis, spasm, or ectasia. Endothelial cells and another cel-
lular milieu might also be involved.22 In smaller vessels, the 
increased contact surface area and higher resistance to blood 
flow may contribute to the interaction of circulating cells to 
promote migration and differentiation. However, in larger ves-
sels, the opposite situation might hamper cellular responses, 
causing a worse strut coverage after stenting.
Our previous randomized trial demonstrated a significant 
correlation between the post-procedural percentage of malap-
posed struts and strut coverage at 3 months after DES implan-
tation.6 In acute coronary syndrome, retained thrombus or 
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strut penetration into necrotic core contributes to the occur-
rence of malapposition after stenting.23 The use of OCT may 
play a beneficial role in improving strut coverage or predicting 
the risk of uncovered or malapposed struts; however, further 
investigation is warranted to determine the association be-
tween strut coverage and procedural or clinical outcomes in 
the patients with AMI. Furthermore, our analysis showed that 
the percentage of uncovered struts was still high (up to 13%) 
in lesions, even without any risk factor determined. This may 
support the rationale for more potent antiplatelet therapy with 
ticagrelor to minimise stent thrombosis in patients with AMI.
Rate of uncovered struts in the present study was higher than 
our initial assumption, which was adopted from previous 
3-month OCT follow-up study of non-MI patients.10 Possible 
reasons for the higher incidence of uncovered struts are as fol-
lows: 1) target population was definitely different from other 
OCT studies: diagnosis of patients enrolled in the present study 
was AMI, and 70% had ST-elevation AMI, expected to have 
worse coverage at early period; 2) most patients visited the 
emergency room and underwent urgent PCI, so clinical dete-
rioration might inhibit healthy vascular healing; and 3) appro-
priate stent or balloon selection and complete apposition us-
ing full OCT assessment would be difficult in an emergency 
setting. Acute stent malapposition after PCI occurred in >70% 
patients in this study. As previously demonstrated, higher 
malapposition rate might aggravate strut coverage at 3-month 
OCT.6 Meanwhile, co-administered drugs such as statins and 
the use of new-generation DES might affect strut coverage. A 
future study, which assesses strut coverage according to dif-
ferent stent types, is required.
Importantly, our trial was terminated before full enroll-
ment, in addition to being underpowered to identify a prima-
ry endpoint difference between two groups. Therefore, it may 
not be appropriate to refer to the present study to draw any def-
inite conclusions regarding the effect of ticagrelor on the pri-
mary endpoint. Selection bias might have occurred, as there 
were only 106 patients who were included in the study despite 
the large inclusion and few exclusion criteria. Second, we did 
not evaluate the degree of platelet inhibition and plasma ade-
nosine level in this study. The question of whether neointimal 
response is driven by P2Y12 inhibition or adenosine-like effects 
remains unanswered.24 Although strut coverage is known to 
be an important factor associated with clinical outcomes after 
stent implantation in pathologic and OCT studies, further study 
is needed to investigate the clinical implications of strut cov-
erage at an early phase, and its roles in AMI.19,25 Third, values 
used for power calculation were arbitrary. Although we pre-
defined the 2% absolute difference of uncovered strut rate as 
the effect of ticagrelor, we still had insufficient evidence to dem-
onstrate whether the treatment can reduce incidence of uncov-
ered strut, and how much clinical significance is provided by the 
improvement of early neointimal healing. Finally, since 3-month 
OCT findings were assessed in this study for the evaluation of 
early neointimal responses in patients with AMI after stent 
implantation, a further extension beyond 3-month follow-up 
might be required.
In conclusion, we were not able to determine the favorable 
effect of ticagrelor on 3-month vascular healing after DES im-
plantation, due to the early termination of the current OCT 
study. Vessel diameter and stent apposition were associated 
strut coverage in the present study. However, our findings 
were not conclusive, and should only be considered for gen-
erating hypothesis, due to the current study’s premature termi-
nation and small number of study population. Adequately 
powered studies are needed to clarify the short- and long-term 
effects of ticagrelor on strut coverage, and to explain the mech-
anisms for improved clinical outcomes by ticagrelor use.
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